Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Active not recruiting × Carcinoma × cabazitaxel × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 7 Recurrence 2 Prostate Cancer, Hereditary, 7 1 Neoplasms 1 Metastatic Castration-resistant Prostate Cancer 1 Carcinoma 1 Adenocarcinoma 1

Interventions

pembrolizumab 9 Cisplatin 9 Carboplatin 7 Paclitaxel 6 durvalumab 5 Pemetrexed 4 Magnetic Resonance Spectroscopy 4 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 4 osimertinib 3 Taxes 3 Specimen Handling 3 Nivolumab 3 Gemcitabine 3 Docetaxel 3 Bevacizumab 3 cabozantinib 2 atezolizumab 2 Sunitinib 2 Radiotherapy, Intensity-Modulated 2 Radiation 2 Platinum 2 Ipilimumab 2 Immunoglobulin G 2 Disulfides 2 CP protocol 2 1,2-diaminocyclohexaneplatinum II citrate 2 trifluridine tipiracil drug combination 1 tremelimumab 1 relatlimab 1 regorafenib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02202772 2025-02-24

CGC

Columbia University

Phase 1/2 Active not recruiting

Carcinoma, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡